Cetuximab in non-small-cell lung cancer.
作者： Robert Pirker , Martin Filipits , None
DOI: 10.3978/J.ISSN.2218-6751.11.01
关键词:
摘要: Cetuximab is a chimeric monoclonal antibody that directed towards the epidermal growth factor receptor (EGFR). It has been evaluated in combination with first-line chemotherapy several phase II and two III trials patients advanced NSCLC. The FLEX trial demonstrated improved survival for cetuximab combined cisplatin plus vinorelbine compared to alone. BMS099 failed show significant improvement progression-free but resulted hazard ratio death similar one seen trial. A meta-analysis of four randomized confirmed efficacy when added chemotherapy. EGFR expression levels based on an immunohistochemistry score have recently shown predict benefit from In high expression, had prolonged treated low outcome was not different between treatment arms. Thus platinum-based represents new option NSCLC their tumors. also chemoradiotherapy stage
amegroups.com参考文章(31)
Robert Pirker, Martin Filipits, None, Targeted therapies in lung cancer. Current Pharmaceutical Design. ,vol. 15, pp. 188- 206 ,(2009) , 10.2174/138161209787002915
Chandra P. Belani, Marshall T. Schreeder, Ronald G. Steis, Richard A. Guidice, Thomas A. Marsland, Elizabeth H. Butler, Suresh S. Ramalingam, Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer Cancer. ,vol. 113, pp. 2512- 2517 ,(2008) , 10.1002/CNCR.23902
Robert Pirker, Martin Filipits, None, Monoclonal antibodies against EGFR in non-small cell lung cancer. Critical Reviews in Oncology Hematology. ,vol. 80, pp. 1- 9 ,(2011) , 10.1016/J.CRITREVONC.2010.10.008
Joan H. Schiller, Joachim von Pawel, Philipp Schütt, Rafat H. Ansari, Michael Thomas, Mansoor Saleh, Robert D. McCroskey, Wolfgang Pfeifer, Thomas A. Marsland, Goetz H. Kloecker, Martin Sebastian, Robert Pirker, Raffael Kurek, Claire Beadman, Mark A. Socinski, Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer Journal of Thoracic Oncology. ,vol. 5, pp. 1977- 1985 ,(2010) , 10.1097/JTO.0B013E3181F4A5C9
Udo Vanhoefer, Mitra Tewes, Federico Rojo, Olaf Dirsch, Norbert Schleucher, Oliver Rosen, Joachim Tillner, Andreas Kovar, Ada H. Braun, Tanja Trarbach, Siegfried Seeber, Andreas Harstrick, José Baselga, Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor Journal of Clinical Oncology. ,vol. 22, pp. 175- 184 ,(2004) , 10.1200/JCO.2004.05.114
Fred R. Hirsch, Roy S. Herbst, Christine Olsen, Kari Chansky, John Crowley, Karen Kelly, Wilbur A. Franklin, Paul A. Bunn, Marileila Varella-Garcia, David R. Gandara, Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy Journal of Clinical Oncology. ,vol. 26, pp. 3351- 3357 ,(2008) , 10.1200/JCO.2007.14.0111
Thomas J. Lynch, Taral Patel, Luke Dreisbach, Michael McCleod, William J. Heim, Robert C. Hermann, Eugene Paschold, Nicholas O. Iannotti, Shaker Dakhil, Steven Gorton, Virginie Pautret, Martin R. Weber, Donald Woytowitz, Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099 Journal of Clinical Oncology. ,vol. 28, pp. 911- 917 ,(2010) , 10.1200/JCO.2009.21.9618
A. Ardizzoni, L. Boni, M. Tiseo, F. V. Fossella, J. H. Schiller, M. Paesmans, D. Radosavljevic, A. Paccagnella, P. Zatloukal, P. Mazzanti, D. Bisset, R. Rosell, Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis Journal of the National Cancer Institute. ,vol. 99, pp. 847- 857 ,(2007) , 10.1093/JNCI/DJK196
E. Felip, C. Gridelli, P. Baas, R. Rosell, R. Stahel, Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010 Annals of Oncology. ,vol. 22, pp. 1507- 1519 ,(2011) , 10.1093/ANNONC/MDR150
Charles A. Butts, David Bodkin, Edward L. Middleman, Craig W. Englund, David Ellison, Yasmin Alam, Harvey Kreisman, Peter Graze, James Maher, Helen J. Ross, Peter M. Ellis, William McNulty, Edward Kaplan, Virginie Pautret, Martin R. Weber, Frances A. Shepherd, Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 25, pp. 5777- 5784 ,(2007) , 10.1200/JCO.2007.13.0856